GLP-1 receptor agonists have become central managing type 2 diabetes and obesity. Their relevance in hepatology is now coming into sharper focus.
In August 2025, the FDA approved Wegovy (semaglutide) for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis, using the accelerated approval pathway based on histologic surrogate endpoints.
Even as semaglutide establishes its role in this space, a parallel body of evidence is around alcohol use disorder (AUD) and alcohol-associated liver disease. Together, these developments position GLP-1 receptor agonists as a drug class with potentially complementary roles across the spectrum of liver disease.
A Liver Indication of Their Own
The FDA approval of semaglutide for MASH was supported by interim results from the ongoing phase 3 ESSENCE trial. In the planned interim analysis, 63% of participants receiving semaglutide achieved MASH resolution without worsening of fibrosis, compared with 34% receiving placebo.
Semaglutide’s approval follows that of resmetirom, a selective thyroid hormone receptor-beta agonist, offering a mechanistically distinct pharmacologic option for steatohepatitis with fibrosis.
These agents act through different pathways: resmetirom via hepatic thyroid hormone receptor-beta signaling and semaglutide primarily through systemic metabolic effects mediated by GLP-1 receptor agonism. Whether combination therapy provides additive benefit remains an open question.
Clinical pathways are already adapting. The American Gastroenterological Association has updated its MASLD care pathway to incorporate both agents, with treatment selection guided by disease stage, metabolic comorbidities, and tolerability.
Not Just Weight Loss
A persistent misconception is that GLP-1 receptor agonists improve liver disease by “shrinking” the patient. Although weight loss plays an important role, it does not fully explain the hepatic effects observed with semaglutide.
GLP-1 receptors are not expressed on hepatocytes or hepatic stellate cells, supporting that much of the benefit is mediated through extrahepatic pathways involving the brain, gastrointestinal tract, adipose tissue, and pancreas.
At the same time, emerging evidence suggests that liver sinusoidal endothelial cells may represent an intrahepatic GLP-1 receptor-bearing population that contributes to weight-independent hepatoprotection.
This concept is supported by multiple datasets. A secondary analysis from the ESSENCE trial showed improvements in aminotransferases, MASH resolution, elastography metrics, and fibrosis that were not fully explained by weight change.
Proteomic studies have also identified biomarker patterns associated with MASH resolution in semaglutide-treated patients that reflect metabolic, inflammatory, and fibrotic pathways beyond weight loss alone.
Semaglutide’s accelerated approval was based on surrogate histologic endpoints. Whether these improvements translate into reductions in hepatic decompensation, transplantation, and liver-related mortality remains to be determined.
A Drug That Curbs More Than Appetite
While semaglutide has been advancing in MASH, a separate body of evidence has been developing in AUD.
Clinical data show that semaglutide reduces drinks per drinking day, alcohol craving, and heavy drinking trajectories compared with placebo in adults with AUD.
The likely mechanism involves GLP-1 receptor signaling within mesolimbic reward circuitry, where receptor activation attenuates alcohol reinforcement in a manner similar to its effects on food reward.
An important question is whether GLP-1 receptor agonists can protect the liver even when alcohol intake does not change. Preclinical and translational data suggest that GLP-1 receptor agonism can reduce ethanol-related hepatoxicity by modulating ethanol metabolism and limiting the formation of toxic metabolites that drive hepatocellular injury. Notably, these hepatoprotective effects have been observed even in settings where alcohol intake itself is unchanged.
Evidence Meets Clinical Practice
Many patients with liver disease present with overlapping metabolic dysfunction and alcohol use, now categorized as metabolic and alcohol-associated liver disease (MetALD) under updated steatotic liver disease nomenclature.
In this phenotype, both obesity-related lipogenesis and alcohol-mediated hepatotoxicity contribute to fibrosis progression. Historically, no single pharmacologic class has addressed both pathways simultaneously.
GLP-1 receptor agonists may help bridge this gap. These agents improve metabolic risk factors and steatohepatitis biology, may reduce alcohol craving and heavy drinking, and may attenuate alcohol-related liver injury through liver-directed metabolic pathways.
Early disease-specific data suggest attenuation of liver disease progression in patients with MetALD treated with GLP-1 receptor agonists.
Summary
GLP-1 receptor agonists are increasingly relevant in hepatology, extending beyond their established roles in diabetes and obesity. Evidence of hepatic benefit independent of weight loss, paired with early hepatoprotection signals in AUD, suggests a broader role across the steatotic liver disease continuum.
Eugenia Tsai, MD, is a transplant hepatologist with the Texas Liver Institute in San Antonio, Texas, and assistant professor at UT Health San Antonio. She also serves as the medical director of the liver transplant program at University Health Transplant Institute.